Biosimilars: Current Scientific and Regulatory Considerations

E-ISSN： 2212-3938|9|1|53-63

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.9, Iss.1, 2014-02, pp. : 53-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 3, 2015-12 ,pp. : 158-164

Bentham Science Publishers

Access to resources Recommend Favorite

Biosimilars of Biological Drug Therapies: Regulatory, Clinical and Commercial Considerations

By Dranitsaris George

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1527-1536

Adis International

Access to resources Recommend Favorite

Biosimilars: Current Status

By Kuhlmann Martin K.

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 3, 2007-01 ,pp. : 199-206

Adis International

Access to resources Recommend Favorite

Current issues in biowaivers and biosimilars

By Endrenyi Laszlo

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 139-142

Informa Healthcare

Access to resources Recommend Favorite

Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations

By Wang Yow-Ming Chow Andrew

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 46-61

Taylor & Francis Ltd

Access to resources Recommend Favorite